Physician profile
Adi E Mehta
NPI 1679620330
$119,816.96
in general payments reported to CMS, 2019-2025
10 companies · $96.81 in 2025
The $96.81 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $11K · 2021: $38K · 2022: $27K · 2023: $6,085 · 2024: $150 · 2025: $96.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,928 · Travel and Lodging: $956 · Food and Beverage: $351 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,928.00 |
| Travel and Lodging | $955.70 |
| Food and Beverage | $350.91 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101,650.72 | 2019-2025 | Saxenda |
| Merck Sharp & Dohme LLC | $11,068.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,333.68 | 2019-2022 | |
| Lilly USA, LLC | $2,961.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $318.49 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $162.10 | 2019 | |
| Stryker Corporation | $150.07 | 2024 | Actishield |
| Abbott Laboratories | $82.00 | 2022 | |
| Integra Lifesciences Corporation | $75.84 | 2023 | Tenoglide |
| Bayer Healthcare Pharmaceuticals INC. | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adi Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.